NEW YORK (Reuters) - Pfizer appointed a former chief executive officer at Vanguard, the drug giant's biggest investor, to its ...

The corporate clash between Pfizer and Starboard Value heated up on Thursday when the activist investment firm pressed the ...

Hedge fund Starboard Value's activist campaign targeting Pfizer (PFE) divides Wall Street, with analysts questioning the ...

Will this clash between a major shareholder and management, current and former, harm the stock? Or is the situation merely an ...

Speculation surrounds the reversal, with Jeff Smith, CEO of Starboard, claiming Pfizer pressured the ex-executives with ...

Now, despite playing no formal role in the battle between Pfizer and Starboard, Guggenheim has found itself in the crossfire of one of the messiest activist campaigns in recent Wall Street memory.

In another twist to the tale of Starboard Value's push for change at Pfizer, the activist investor has claimed former ...

Barely three years since its coronavirus vaccine helped stem the pandemic, Pfizer’s stock has lost 50 percent of its value ...

Pharmaceutical giant Pfizer (PFE) is butting heads with activist investor Starboard Value, as Starboard demands an ...

On Wednesday, Bourla is expected to sit down with Starboard after reports early last week that the investment firm had ...

On Oct. 6, The Wall Street Journal reported that activist investor group Starboard Value owns a stake in Pfizer ( PFE -0.61%) ...

Activist investor Starboard Value accused Pfizer of pressuring its former CEO Ian Read and ex-CFO Frank D’Amelio to halt ...